The Avicenna Alliance has officially submitted its contributions to both the European Commission’s public consultation on the revision of the EU general pharmaceuticals legislation as well as DG SANTE’s accompanying study.
These dossiers are important for the in silico medicine community because the general pharmaceutical legislation revision provides a key opportunity to incorporate the acceptance of in silico evidence into EU legislation. The pharmaceutical legislation has a broad realm of relevant topics, covering access to medicines, cost of medicines, environmental impact, unmet medical needs, etc., all of which the usage of in silico technologies could positively impact.
If you want to be updated about the latest news on pharmaceutical legislation and statistics of feedback instances received, have a look HERE.
